HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TNXP
Tonix Pharmaceuticals Holding Corp.
There isn't enough reported data to score TNXP yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TNXP Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
TNXP's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TNXP PE Valuation
TNXP has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TNXP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect TNXP's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TNXP Earnings Per Share
TNXP and HIMS do not have enough comparable growth data to identify a winner.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over TNXP on profitability, with a higher operating margin.
TNXP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $17.2M | +424% |
| Q2 2026 | $13.5M | +578% |
| Q1 2026 | $6.9M | +183% |
| Q4 2025 | $5.4M | +109% |
| Q3 2025 | $3.3M | +17% |
| Q2 2025 | $2M | -9.5% |
| Q1 2025 | $2.4M | -2.1% |
| Q4 2024 | $2.6M | -32% |
TNXP's revenue has grown year over year for five quarters in a row: $17M last quarter, up 424% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -322% | +683 points |
| Q2 2026 | -314% | +1102 points |
| Q1 2026 | -604% | +57 points |
| Q4 2025 | -896% | -25 points |
| Q3 2025 | -1005% | -454 points |
| Q2 2025 | -1416% | +2085 points |
| Q1 2025 | -661% | +199 points |
| Q4 2024 | -871% | -148 points |
TNXP's operating margin was −322% last quarter, up 683 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TNXP on cash generation, producing positive trailing cash flow while its opponent burns cash.
TNXP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$41.7M | -$11.9M |
| Q2 2026 | -$42.8M | -$27.5M |
| Q1 2026 | -$44M | -$27.4M |
| Q4 2025 | -$41.5M | -$26.9M |
| Q3 2025 | -$29.7M | -$10.9M |
| Q2 2025 | -$15.4M | -$5.4M |
| Q1 2025 | -$16.6M | +$1.1M |
| Q4 2024 | -$14.6M | +$8.1M |
TNXP has burned cash in almost every quarter: −$170M over the past year, against −$76M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TNXP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TNXP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +1.8M shares |
| 1 year | +152% | +11.1M shares |
TNXP has 18M diluted shares, up 152% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $7.8M |
| Q3 2025 | — |
| Q2 2025 | $2.9M |
| Q1 2025 | $3M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $14M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TNXP Net Leverage
TNXP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TNXP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.4 | Oversold |
| Stochastic | 1.2 | Oversold |
TNXP's weekly RSI is 24 (oversold) and its Stochastic is 1 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TNXP PE vs Healthcare Sector
TNXP has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TNXP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.29 | 48% below |
| 20 week MA | $9.72 | 67% below |
| 50 week MA | $12.7 | 74% below |
| 100 week MA | $20.0 | 84% below |
| 200 week MA | $1,860.9 | 100% below |
TNXP is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over TNXP on returns for 2026, with the stronger performance.
TNXP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $704,000.0 | $425,600.0 | -40% |
| 2021 | $425,600.0 | $256,064.0 | -40% |
| 2022 | $256,064.0 | $6,640.0 | -97% |
| 2023 | $6,640.0 | $1,289.6 | -81% |
| 2024 | $1,289.6 | $33.8 | -97% |
| 2025 | $33.8 | $16.3 | -52% |
| 2026 YTD | $16.3 | $3.24 | -80% |
TNXP has finished every year since 2020 lower, and it's down 80% so far in 2026.